Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Crinetics Pharmaceuticals, Inc. - Common Stock
(NQ:
CRNX
)
53.60
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
118
Open
53.60
Bid (Size)
52.57 (2)
Ask (Size)
54.03 (1)
Prev. Close
53.60
Today's Range
53.60 - 53.60
52wk Range
33.67 - 62.53
Shares Outstanding
54,026,103
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
December 16, 2024
Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel approach to hormone regulation.
Via
Benzinga
Exposures
Product Safety
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
December 16, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
+51.46%
+51.46%
1 Month
-4.39%
-4.39%
3 Month
+6.31%
+6.31%
6 Month
+17.39%
+17.39%
1 Year
+48.44%
+48.44%
More News
Read More
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
What Analysts Are Saying About Crinetics Pharmaceuticals Stock
September 27, 2024
Via
Benzinga
A Closer Look at 11 Analyst Recommendations For Crinetics Pharmaceuticals
August 09, 2024
Via
Benzinga
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
December 09, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
November 15, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
November 14, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
November 12, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 11, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
October 16, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
October 08, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
October 08, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
September 26, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
August 29, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 12, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
August 08, 2024
Via
InvestorPlace
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
August 08, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
July 18, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
July 14, 2024
Via
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.